Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
8
×
detroit top stories
fda
8
×
indiana blog main
indiana top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
8
×
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
8
×
wisconsin blog main
wisconsin top stories
clinical trials
national
cancer
eli lilly
cancer immunotherapy
drugs
food and drug administration
investing
nonalcoholic steatohepatitis
startups
teva pharmaceutical
abbvie
amgen
What
drug
8
×
fda
approval
roundup
won
annual
approved
attention
bio
biotech
cancer
class
companies
developed
drugs
meeting
migraine
new
oral
potential
prices
afternoon
agency
ahead
aimmune
allergy
alzheimer’s
ambien
american
amgen
anticipated
arguments
asco
assessed
attendees
awaited
awarded
big
blueprint
camp’s
Language
unset
Current search:
drug
×
biotech
×
" detroit blog main "
×
" raleigh-durham blog main "
×
fda
×
" texas top stories "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
@xconomy.com
6 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details